Therapeutics for the management of cytokine release syndrome in COVID-19.
Curr Top Med Chem
; 2022 Jul 07.
Article
in English
| MEDLINE | ID: covidwho-2260561
ABSTRACT
Coronavirus disease (COVID-19) is the greatest pandemic of this era and has affected more than 10 million people across 213 nations. However, the etiology, management, and treatment of COVID-19 remain unknown. A better understanding of the novel virus would help in developing accurate diagnostic methods and efficacious drugs for the treatment of patients of all age groups. To control the pandemic urgently, many drugs are being repurposed and several clinical trials are in progress for the same. As cytokine storm has been observed to be one of the common mechanisms of immune response in COVID-19 patients, several drugs are under trials to control the cytokine storm. In this review, we discuss the different categories of drugs in clinical trials for the management of cytokine storms in COVID-19 patients. Hitherto, several promising candidates such as IL-1 and IL-6 inhibitors have failed to display efficacy in the trials. Only corticosteroid therapy has shown benefit so far, albeit limited to patients on ventilator support. Thus, it is crucial to seek novel strategies to combat hyperinflammation and increase survival in COVID-19 afflicted patients.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Type of study:
Etiology study
/
Experimental Studies
/
Prognostic study
/
Randomized controlled trials
Language:
English
Journal subject:
Chemistry
Year:
2022
Document Type:
Article
Affiliation country:
1568026622666220707114121
Similar
MEDLINE
...
LILACS
LIS